1-2 of 2
Paul A. Vasey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

Gillian Gifford, Jim Paul, Paul A. Vasey, Stanley B. Kaye, Robert Brown, on behalf of the Scottish Gynaecological Clinical Trials Group
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4420–4426.
https://doi.org/10.1158/1078-0432.CCR-03-0732
Published: 06 July 2004
View article titled, The Acquisition of <em>hMLH1</em> Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients
Open the PDF for The Acquisition of <em>hMLH1</em> Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

Paul A. Vasey, Stan B. Kaye, Rosemary Morrison, Chris Twelves, Peter Wilson, Ruth Duncan, Alison H. Thomson, Lilian S. Murray, Tom E. Hilditch, Tom Murray, Sally Burtles, D. Fraier, E. Frigerio, Jim Cassidy, on behalf of the Cancer Research Campaign Phase I/II Committee
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 83–94.
Published: 01 January 1999
View article titled, Phase I Clinical and Pharmacokinetic Study of PK1 [<em>N</em>-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
Open the PDF for Phase I Clinical and Pharmacokinetic Study of PK1 [<em>N</em>-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates in another window